N/A
N=36
Effects of Konjac Glucomannan Noodle Intervention in Subjects With Metabolic Syndrome
Metabolic Syndrome
Bottom Line
View on ClinicalTrials.gov: NCT02711306 ↗Enrolled (actual)
36
Serious AEs
0.0%
Results posted
Oct 2019
Primary outcome: Primary: Body Weight — 75.2; 74.97; 74.41; 74.39 kg
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Glucomannan noodle (Dietary_supplement); Placebo noodle (Dietary_supplement)
- Age
- Adult · 20+ yrs
- Sex
- All
- Sponsor
- Taipei Medical University
- Primary completion
- Jan 2014
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Body Weight |
75.2; 74.97; 74.41; 74.39 | — |
| SECONDARY Waist Circumference |
92.03; 91.14; 90.17; 90.15 | — |
| SECONDARY Glycemic Index |
7.28; 7.21; 7.08; 7.12 | — |
| SECONDARY Lipid Index |
133.86; 135.39; 137.24; 130.53 | — |
Summary
Metabolic syndrome (MS) is a complex disease with a cluster of risk factors and clinical features, which includes central or abdominal obesity, atherogenic dyslipidemia, impaired glucose regulation, hyperinsulinemia, high blood pressure, and concomitance of pro-inflammatory cytokine and insulin resistance. Glucomannan (GM) is a water-soluble dietary fiber derived from the root of Amorphophallus konjac that can improve blood sugar, blood fat concentration, and weight management, and has other health benefits.The purposes of this study are going to investigate the effects of KGM noodle (KGN) as stable food to MS and diabetic patients.
Eligibility Criteria
Inclusion Criteria: Adults with metabolic syndrome
Subjects were considered to have metabolic syndrome if subjects had 3 of the following 5 characteristics:
- Abdominal obesity (waist circumference >= 90 cm in men and >= 80 cm in women)
- Impaired fasting glucose ( >= 5.6 mmol/L)
- Hypertriglyceridemia ( >= 1.7 mmol/L)
- Low HDL-C ( = 130 mmHg and DBP >= 85 mmHg).
Exclusion Criteria
- Liver and renal diseases
- Undergoing statin therapy
- Pregnancy women
- Taking antioxidant vitamins supplements
Data sourced from ClinicalTrials.gov (NCT02711306). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.